

# Genetic variation impacts pharmacokinetics of exemestane

August 3 2017

---



(HealthDay)—The *OATP1B1* c.521>C single nucleotide polymorphism

(SNP) influences exemestane pharmacokinetics in healthy postmenopausal women, according to a study published online July 29 in the *Journal of Clinical Pharmacy and Therapeutics*.

B.J. Gregory, Pharm.D., from the Harding University College of Pharmacy in Searcy, Ark., and colleagues conducted a retrospective pharmacogenetic study to examine the impact of the *OATP1B1* c.521T>C SNP (rs4149056) on the pharmacokinetics of exemestane in [healthy volunteers](#). Exemestane was administered orally to 14 healthy postmenopausal women; they were all sampled for pharmacokinetic analyses and genotyped retrospectively.

The researchers found that five of the subjects were carriers of the minor C allele (*OATP1B1* c.521TC+ CC) and nine were carriers of *OATP1B1* c.521TT genotype. Over eight-hours post-dosing, pharmacokinetics were analyzed. The *OATP1B1* genotype groups had statistically significant differences in the plasma exemestane area under the curve ( $AUC_{0-8}$ ) ( $P = 0.04$ ). Statistically significant differences were also seen in the plasma  $AUC_{0-8}$  of 17-hydroexemestane between the *OATP1B1* genotype groups ( $P = 0.04$ ).

"Our data suggest that the *OATP1B1* c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Genetic variation impacts pharmacokinetics of exemestane (2017, August 3) retrieved 25 April 2024 from <https://medicalxpress.com/news/2017-08-genetic-variation-impacts-pharmacokinetics->

[exemestane.html](#)

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.